PLoS ONE (Jan 2015)

Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study.

  • Ylenia Ingrasciotta,
  • Janet Sultana,
  • Francesco Giorgianni,
  • Andrea Fontana,
  • Antonio Santangelo,
  • Daniele Ugo Tari,
  • Domenico Santoro,
  • Vincenzo Arcoraci,
  • Margherita Perrotta,
  • Luisa Ibanez,
  • Gianluca Trifirò

DOI
https://doi.org/10.1371/journal.pone.0122899
Journal volume & issue
Vol. 10, no. 4
p. e0122899

Abstract

Read online

BACKGROUND:Non-steroidal anti-inflammatory agents (NSAIDs) are known to be associated with renal damage. No clear evidence exists regarding differential risk of chronic kidney disease (CKD), specifically, across various NSAIDs. AIM:The aim of this population-based case-control study was to evaluate the association between use of individual NSAIDs and risk of CKD in a general population of Southern Italy. METHODS:A nested case-control study was carried out using the general practice Arianna database, identifying incident CKD patients as cases and matched controls from 2006 to 2011. The date of first CKD diagnosis was defined as the index date (ID). Conditional logistic regressions were performed to estimate the risk of CKD associated with NSAIDs by class and individual drugs as compared to non-use during different time windows (within one year, six or three months prior to ID), with the latter being defined as current users. Among current users, the effect of cumulative exposure to these drugs was evaluated. RESULTS:Overall, 1,989 CKD cases and 7,906 matched controls were identified. A statistically significant increase in the risk of CKD was found for current users of oxicams (adjusted OR: 1.68; 95% CI: 1.15-2.44) and concerning individual compounds, for ketorolac (adj. OR: 2.54; 95% CI: 1.45-4.44), meloxicam (adj. OR: 1.98; 95% CI: 1.01-3.87) and piroxicam (adj. OR: 1.95; 95% CI: 1.19-3.21). CONCLUSIONS:The risk of CKD varies across individual NSAIDs. Increased risk has been found for ketorolac, which may precipitate subclinical CKD through acute renal damage, and long-term exposure to oxicams, especially meloxicam and piroxicam.